EXPLORE!

Serum Institute Life Sciences -Biocon Biologic Deal Cleared

  696 Views

#Multispeciality 

PTI    19 May 2022

The Competition Commission of India, CCI has approved the deal between SII’s Covishield technology and Biocon Biologics. As per the deal details, SII will acquire a 15% stake in Biocon Biologics Ltd. Covishield Technologies Pvt. Ltd., a subsidiary owned by SII, that was initially established to undertake the business of marketing, selling, and distributing vaccines and other life-saving drugs will be merged into Biocon Biologics Ltd.

Biocon Ltd. is a subsidiary of Biocon Biologics Ltd. that offers treatments such as Diabetes, Oncology, cancer, auto-immune diseases, etc. with fully dedicated research and development centers, and manufacturing facilities.

Source: The Economic Times

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.